Cancer Research Meeting Calendar Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zarour, H. M.
Right arrow Articles by Kirkwood, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zarour, H. M.
Right arrow Articles by Kirkwood, J. M.
[Cancer Research 62, 213-218, January 1, 2002]
© 2002 American Association for Cancer Research

Immunology

NY-ESO-1 119–143 Is a Promiscuous Major Histocompatibility Complex Class II T-Helper Epitope Recognized by Th1- and Th2-Type Tumor-reactive CD4+ T Cells1

Hassane M. Zarour2, Bernard Maillere, Vladimir Brusic, Kara Coval, Eileen Williams, Sandra Pouvelle-Moratille, Florence Castelli, Stephanie Land, Jaafar Bennouna, Theodore Logan and John M. Kirkwood

Department of Medicine and Melanoma Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 [H. M. Z., K. C., E. W., J. M. K.]; Protein Engineering and Research Department, CEA-Saclay, 91191 Gif sur Yvette, France [B. M., S. P-M., F. C.]; Kent Ridge Digital Labs, Singapore 119613 [V. B.]; Biostatistics, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 [S. L.]; Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 [J. B.]; and Indianapolis Cancer Research Institute, Indianapolis, Indiana 46202 [T. L.]

The NY-ESO-1 gene product is expressed by a range of human tumors and is recognized by antibodies from sera of cancer patients with NY-ESO-1-expressing tumors. The NY-ESO-1 gene also encodes several MHC class I- and MHC class II-restricted tumor epitopes recognized by T lymphocytes. In particular, we previously reported that the NY-ESO-1 119–143 peptide contains at least two HLA-DRB1*0401-presented epitopes that are recognized by melanoma-reactive CD4+ T cells. Here we report that the NY-ESO-1 119–143 peptide can be presented in the context of multiple HLA-DR alleles to stimulate tumor-reactive CD4+ T cells. The NY-ESO-1 119–143 peptide is able to bind to several DR molecules. The NY-ESO-1 119–143 peptide is also capable of inducing specific CD4+ T cells in vitro from peripheral blood lymphocytes of normal donors and patients with melanoma who express these HLA-DR alleles. These CD4+ T cells recognize NY-ESO-1+, HLA-matched or autologous melanoma cell lines, as well as autologous antigen-presenting cells fed with the NY-ESO-1 protein. We also demonstrate that the NY-ESO-1 119–143 peptide stimulates in vitro both Th1-type and Th2-type CD4+ T-cell responses from peripheral blood lymphocytes of normal donors and melanoma patients. Taken together, these data suggest a key role of the NY-ESO-1 119–143 peptide sequence in the induction of cellular and humoral responses against NY-ESO-1-expressing tumors. They support the relevance of cancer vaccine trials with the NY-ESO-1 119–143 peptide in the large number of cancer patients with NY-ESO-1-expressing tumors.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
G. Bioley, C. Dousset, A. Yeh, B. Dupont, N. Bhardwaj, G. Mears, L. J. Old, M. Ayyoub, and D. Valmori
Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire
Clin. Cancer Res., July 1, 2009; 15(13): 4467 - 4474.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X.-F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillere
Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients
J. Immunol., July 1, 2008; 181(1): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Marturano, R. Longhi, V. Russo, and M. P. Protti
Endosomal Proteases Influence the Repertoire of MAGE-A3 Epitopes Recognized In vivo by CD4+ T Cells
Cancer Res., March 1, 2008; 68(5): 1555 - 1562.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Kudela, B. Janjic, J. Fourcade, F. Castelli, P. Andrade, J. M. Kirkwood, T. El-Hefnawy, M. Amicosante, B. Maillere, and H. M. Zarour
Cross-Reactive CD4+ T Cells against One Immunodominant Tumor-Derived Epitope in Melanoma Patients
J. Immunol., December 1, 2007; 179(11): 7932 - 7940.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Vujanovic, M. Mandic, W. C. Olson, J. M. Kirkwood, and W. J. Storkus
A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6
Clin. Cancer Res., November 15, 2007; 13(22): 6796 - 6806.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Valmori, N. E. Souleimanian, V. Tosello, N. Bhardwaj, S. Adams, D. O'Neill, A. Pavlick, J. B. Escalon, C. M. Cruz, A. Angiulli, et al.
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
PNAS, May 22, 2007; 104(21): 8947 - 8952.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Atanackovic, J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders, K. Bartels, G. Schilling, C. Faltz, C. Wolschke, J. Dierlamm, et al.
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Blood, February 1, 2007; 109(3): 1103 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Janjic, P. Andrade, X.-F. Wang, J. Fourcade, C. Almunia, P. Kudela, A. Brufsky, S. Jacobs, D. Friedland, R. Stoller, et al.
Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers
J. Immunol., August 15, 2006; 177(4): 2717 - 2727.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Hasegawa, Y. Noguchi, F. Koizumi, A. Uenaka, M. Tanaka, M. Shimono, H. Nakamura, H. Shiku, S. Gnjatic, R. Murphy, et al.
In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15-Binding CD4 T-Cell Epitope
Clin. Cancer Res., March 15, 2006; 12(6): 1921 - 1927.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Neumann, C. Wagner, K.-D. Preuss, B. Kubuschok, C. Schormann, S. Stevanovic, and M. Pfreundschuh
Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells
Blood, November 1, 2005; 106(9): 3105 - 3113.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Paschen, M. Song, W. Osen, X. D. Nguyen, J. Mueller-Berghaus, D. Fink, N. Daniel, M. Donzeau, W. Nagel, H. Kropshofer, et al.
Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2-Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice
Clin. Cancer Res., July 15, 2005; 11(14): 5241 - 5247.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Mandic, F. Castelli, B. Janjic, C. Almunia, P. Andrade, D. Gillet, V. Brusic, J. M. Kirkwood, B. Maillere, and H. M. Zarour
One NY-ESO-1-Derived Epitope That Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma
J. Immunol., February 1, 2005; 174(3): 1751 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. A. Vaughan, S. Svobodova, D. MacGregor, S. Sturrock, A. A. Jungbluth, J. Browning, I. D. Davis, P. Parente, Y.-T. Chen, E. Stockert, et al.
Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1
Clin. Cancer Res., December 15, 2004; 10(24): 8396 - 8404.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. D. Davis, W. Chen, H. Jackson, P. Parente, M. Shackleton, W. Hopkins, Q. Chen, N. Dimopoulos, T. Luke, R. Murphy, et al.
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
PNAS, July 20, 2004; 101(29): 10697 - 10702.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Korangy, L. A. Ormandy, J. S. Bleck, J. Klempnauer, L. Wilkens, M. P. Manns, and T. F. Greten
Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma
Clin. Cancer Res., July 1, 2004; 10(13): 4332 - 4341.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. I. Webb, M. A. Dunstone, W. Chen, M.-I. Aguilar, Q. Chen, H. Jackson, L. Chang, L. Kjer-Nielsen, T. Beddoe, J. McCluskey, et al.
Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue
J. Biol. Chem., May 28, 2004; 279(22): 23438 - 23446.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. S. Schultz, B. Schuler-Thurner, V. Stroobant, L. Jenne, T. G. Berger, K. Thielemanns, P. van der Bruggen, and G. Schuler
Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy
J. Immunol., January 15, 2004; 172(2): 1304 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Chamoto, T. Tsuji, H. Funamoto, A. Kosaka, J. Matsuzaki, T. Sato, H. Abe, K. Fujio, K. Yamamoto, T. Kitamura, et al.
Potentiation of Tumor Eradication by Adoptive Immunotherapy with T-cell Receptor Gene-Transduced T-Helper Type 1 Cells
Cancer Res., January 1, 2004; 64(1): 386 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Teramoto, K. Kontani, Y. Ozaki, S. Sawai, N. Tezuka, T. Nagata, S. Fujino, Y. Itoh, O. Taguchi, Y. Koide, et al.
Deoxyribonucleic Acid (DNA) Encoding a Pan-Major Histocompatibility Complex Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy
Cancer Res., November 15, 2003; 63(22): 7920 - 7925.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Rodolfo, R. Luksch, E. Stockert, Y.-T. Chen, P. Collini, T. Ranzani, C. Lombardo, P. Dalerba, L. Rivoltini, F. Arienti, et al.
Antigen-Specific Immunity in Neuroblastoma Patients: Antibody and T-Cell Recognition of NY-ESO-1 Tumor Antigen
Cancer Res., October 15, 2003; 63(20): 6948 - 6955.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Mandic, C. Almunia, S. Vicel, D. Gillet, B. Janjic, K. Coval, B. Maillere, J. M. Kirkwood, and H. M. Zarour
The Alternative Open Reading Frame of LAGE-1 Gives Rise to Multiple Promiscuous HLA-DR-restricted Epitopes Recognized by T-helper 1-type Tumor-reactive CD4+ T Cells
Cancer Res., October 1, 2003; 63(19): 6506 - 6515.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Gnjatic, D. Atanackovic, E. Jager, M. Matsuo, A. Selvakumar, N. K. Altorki, R. G. Maki, B. Dupont, G. Ritter, Y.-T. Chen, et al.
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses
PNAS, July 22, 2003; 100(15): 8862 - 8867.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Gnjatic, D. Atanackovic, M. Matsuo, E. Jager, S. Y. Lee, D. Valmori, Y.-T. Chen, G. Ritter, A. Knuth, and L. J. Old
Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs
J. Immunol., February 1, 2003; 170(3): 1191 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. S. Voo, T. Fu, H. E. Heslop, M. K. Brenner, C. M. Rooney, and R.-F. Wang
Identification of HLA-DP3-restricted Peptides from EBNA1 Recognized by CD4+ T Cells
Cancer Res., December 15, 2002; 62(24): 7195 - 7199.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. A. Castelli, C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J.-G. Guillet, A. Menez, B. Georges, et al.
HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity
J. Immunol., December 15, 2002; 169(12): 6928 - 6934.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, R. Omiya, M. Ruiz, E. Huarte, P. Sarobe, J. J. Lasarte, M. Herraiz, B. Sangro, J. Prieto, F. Borras-Cuesta, et al.
Identification of an Antigenic Epitope for Helper T Lymphocytes from Carcinoembryonic Antigen
Clin. Cancer Res., October 1, 2002; 8(10): 3219 - 3225.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.